EyePoint Pharmaceuticals, Inc. (EYPT) News
Filter EYPT News Items
EYPT News Results
|Loading, please wait...|
EYPT News Highlights
- For EYPT, its 30 day story count is now at 7.
- Over the past 12 days, the trend for EYPT's stories per day has been choppy and unclear. It has oscillated between 2 and 3.
- AGE, EYE and AMD are the most mentioned tickers in articles about EYPT.
Latest EYPT News From Around the Web
Below are the latest news stories about EyePoint Pharmaceuticals Inc that investors may wish to consider to help them evaluate EYPT as an investment opportunity.
Myriad (MYGN) delivered earnings and revenue surprises of 0% and 0.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on March 3, 2022
WATERTOWN, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 3, 2022 to report its fourth quarter and full-year 2021 financial results and highlight recent corporate developments. To access the live conference call, plea
EyePoint Pharmaceuticals (NASDAQ:EYPT) announces eight-month interim data from the DAVIO Phase 1 clinical trial of EYP-1901, for the treatment of wet age-related macular degeneration (wet AMD). The data will be presented at the Angiogenesis, Exudation, and Degeneration 2022 virtual meeting. Eight--month interim data from the Phase 1 DAVIO clinical trial show no reports of ocular serious...
EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) price on Friday, February 11, rose 1.11% above its previous days close as an upside momentum from buyers pushed the stocks value to $10.00. A look at the stocks price movement, the close in the last trading session was $9.89, moving within a range at $9.48 and $10.19. The beta value EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT) Could Slash -550.0% Soon Read More »
EyePoint Pharmaceuticals Announces Updated Positive Interim Safety and Efficacy Data from Ongoing Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD
WATERTOWN, Mass., Feb. 12, 2022 /PRNewswire/ -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced updated interim data from the
EyePoint Pharmaceuticals Announces 2022 Clinical Plans and Highlights Recent Corporate and Clinical Achievements
– Updated results from the Phase 1 DAVIO study of EYP-1901 for wet AMD continue to show positive safety and efficacy results out to eight months. Further results to be presented at the February Angiogenesis 2022 virtual meeting – – Phase 2 study for EYP-1901 in wet AMD expected to initiate in Q3 2022 guided by positive Type C meeting with FDA – – Announces appointment of Michael C. Pine as Chief Corporate Development and Strategy Officer – – Record customer demand in Q4 2021 for YUTIQ® and DEXYC
EyePoint Pharmaceuticals Appoints Michael C. Pine as Chief Corporate Development and Strategy Officer
WATERTOWN, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the appointment of Michael C. Pine as Chief Corporate Development and Strategy Officer. Mr. Pine brings over 20 years of business and corporate development expertise, leveraging experience from various roles at small and large pharmaceut
A look at the shareholders of EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) can tell us which group is most powerful...
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) has earned a consensus recommendation of Buy from the five analysts that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 1 year price target among analysts that have updated their coverage 
Founded by Renowned Experts in Ophthalmology and Immunology Launches with $10.5 million Series A Financing Led by Safar Partners to Advance Disease-Modifying Therapy for Ocular Surface Disease into the Clinic BOSTON, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Aramis Biosciences, Inc., a clinical-stage immuno-ophthalmology biopharmaceutical company, today announced its launch and the completion of a $10.5 million Series A financing led by Safar Partners with a strategic investment from a global leader in